SCHEMBL30925305

SCHEMBL30925305

COc1cc2ncnc(Nc3cc(Br)c(O)c(Br)c3)c2cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 3/20 1.00
MKNK1 Q9BUB5 2/20 1.00
ABCG2 Q9UNQ0 3/20 0.76
ABCB1 P08183 1/20 0.76
EGFR P00533 12/20 0.74
KDR P35968 9/20 0.70
RET P07949 7/20 0.68
GAK O14976 3/20 0.68
RIPK2 O43353 1/20 0.68
STK10 O94804 1/20 0.68
FLT3 P36888 1/20 0.68
AAK1 Q2M2I8 1/20 0.68
Q6ZSR9 Q6ZSR9 1/20 0.68
SLK Q9H2G2 1/20 0.68
IRAK4 Q9NWZ3 1/20 0.68
RPS6KA6 Q9UK32 1/20 0.68
ALK Q9UM73 1/20 0.68
KIF5B P33176 5/20 0.67
SRC P12931 2/20 0.67
LCK P06239 3/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL323445 1.00 JAK3 (1.00) JAK3MKNK1ABCG2ABCB1EGFR
SCHEMBL5864733 0.88 JAK3 (0.79) JAK3MKNK1ABCG2ABCB1EGFR
SCHEMBL29372372 0.86 JAK3 (1.00) JAK3MKNK1ABCG2ABCB1EGFR
SCHEMBL29651 0.86 JAK3 (1.00) JAK3MKNK1ABCG2ABCB1EGFR
SCHEMBL29711485 0.86 JAK3 (1.00) JAK3MKNK1ABCG2ABCB1EGFR
SCHEMBL7119275 0.85 JAK3 (0.74) JAK3MKNK1ABCG2EGFRKDR
SCHEMBL5570070 0.84 EGFR (0.85) JAK3MKNK1ABCG2ABCB1EGFR
SCHEMBL5864555 0.84 KDR (0.73) JAK3MKNK1EGFRKDRRET
SCHEMBL6668470 0.84 JAK3 (0.73) JAK3MKNK1EGFRKDRRET
SCHEMBL5467825 0.82 EGFR (1.00) JAK3MKNK1ABCG2ABCB1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4629993-A1 METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS Kartos Therapeutics (US) 2025-10-15 EP disclosed
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 WO disclosed
WO-2024124240-A1 METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS KARTOS THERAPEUTICS (US) 2024-06-13 WO disclosed